Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061500 | 0.86 | ALDH1A1 (0.46) | PTGS1PTGS2PTK2MAPTALDH1A1 | |
| SCHEMBL5762543 | 0.86 | ALDH1A1 (0.46) | MAPTALDH1A1MEN1THRBKMT2A | |
| SCHEMBL32670745 | 0.82 | SLC40A1 (0.43) | PTGS1PTGS2MAPTALDH1A1MEN1 | |
| SCHEMBL30293256 | 0.81 | FFAR4 (0.56) | PTGS1PTGS2PTK2GAALMNA | |
| SCHEMBL2760304 | 0.81 | FFAR4 (0.56) | PTGS1PTGS2PTK2GAALMNA | |
| SCHEMBL19099945 | 0.78 | GAA (0.41) | PTGS1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL9617251 | 0.77 | PTK2 (0.44) | PTGS1PTGS2PTK2MAPTALDH1A1 | |
| SCHEMBL2737218 | 0.77 | L3MBTL1 (0.56) | PTGS1PTGS2PTK2MAPTALDH1A1 | |
| SCHEMBL30505740 | 0.77 | ERN1 (0.51) | PTGS1PTGS2PTK2MAPTALDH1A1 | |
| SCHEMBL15073123 | 0.77 | APP (0.59) | PTGS1PTGS2ALDH1A1THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | PTGS1 3545/4885PTGS2 3651/4885PTK2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.